These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23827936)

  • 1. Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study.
    Furin J; Brigden G; Lessem E; Becerra MC
    Int J Tuberc Lung Dis; 2013 Sep; 17(9):1239-41. PubMed ID: 23827936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Second-Line Anti-Tubercular Drugs.
    Ramachandran G
    Indian J Pediatr; 2019 Aug; 86(8):714-716. PubMed ID: 30924070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy].
    Takashima T; Danno K; Tamura Y; Nagai T; Matsumoto T; Han Y; Ano H; Yoshida H; Kawahara K; Tsuyuguchi I
    Kekkaku; 2006 Jun; 81(6):413-8. PubMed ID: 16838679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAS infusion in treatment of multidrug-resistant tuberculosis.
    Fodor T; Pataki G; Schrettner M
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):187-8. PubMed ID: 10694102
    [No Abstract]   [Full Text] [Related]  

  • 6. Manipulation of solid dosage forms for oral administration to paediatric patients for drug-resistant tuberculosis in South Africa: an observation study.
    Harichander S; Bangalee V; Oosthuizen F
    BMC Pediatr; 2024 Aug; 24(1):520. PubMed ID: 39128996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of causes of drug resistance and therapeutic effects on 27 multi-drug resistant pulmonary tuberculosis patients].
    Ye Z; Pei X; Yang Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1997 Aug; 20(4):234-6. PubMed ID: 10072811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily and twice-daily dosing of p-aminosalicylic acid granules.
    Peloquin CA; Berning SE; Huitt GA; Childs JM; Singleton MD; James GT
    Am J Respir Crit Care Med; 1999 Mar; 159(3):932-4. PubMed ID: 10051275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis.
    Wilson JW; Kelkar P; Frigas E
    Int J Tuberc Lung Dis; 2003 May; 7(5):493-7. PubMed ID: 12757053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant tuberculosis in children from 2003 to 2005: a brief report.
    Shah I
    Indian J Med Microbiol; 2012; 30(2):208-11. PubMed ID: 22664439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
    Park SK; Lee WC; Lee DH; Mitnick CD; Han L; Seung KJ
    Int J Tuberc Lung Dis; 2004 Mar; 8(3):361-8. PubMed ID: 15139476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paediatric use of second-line anti-tuberculosis agents: a review.
    Seddon JA; Hesseling AC; Marais BJ; McIlleron H; Peloquin CA; Donald PR; Schaaf HS
    Tuberculosis (Edinb); 2012 Jan; 92(1):9-17. PubMed ID: 22118883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations.
    Taneja R; Garcia-Prats AJ; Furin J; Maheshwari HK
    Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():61-68. PubMed ID: 26564545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube.
    Reid J; Marciniuk D; Peloquin CA; Hoeppner V
    Chest; 2002 Jan; 121(1):281-4. PubMed ID: 11796464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.
    Kibleur Y; Brochart H; Schaaf HS; Diacon AH; Donald PR
    Clin Drug Investig; 2014 Apr; 34(4):269-76. PubMed ID: 24488376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan.
    Chien JY; Lai CC; Tan CK; Chien ST; Yu CJ; Hsueh PR
    J Antimicrob Chemother; 2013 Aug; 68(8):1910-6. PubMed ID: 23580558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia.
    Tessema B; Beer J; Emmrich F; Sack U; Rodloff AC
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):805-11. PubMed ID: 22390880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.